PMID: 9179275May 1, 1997Paper

Graft versus leukemia (GVL) in the therapy of acute lymphoblastic leukemia (ALL)

Leukemia
F R Appelbaum

Abstract

The ability of T cells that accompany or develop from transplanted allogeneic marrow to eradicate leukemia has been repeatedly demonstrated in animal models. Whether a similar graft-versus-leukemia effect exists in humans who have received transplants for acute lymphoblastic leukemia can be addressed by five different clinical observations: comparisons of autologous versus allogeneic transplantation, comparisons of syngeneic versus allogeneic transplantation, examination of relapse rates in allogeneic recipients who do or do not develop GVHD, the impact of T-cell depletion on relapse rates, and the results of donor lymphocyte infusions to treat posttransplant relapse. The bulk of available evidence supports the view that a potent GVL effect exists in patients treated for ALL. These results provide a strong rationale for efforts to develop techniques to further capitalize on the GVL effect.

Associated Clinical Trials

Jun 18, 2009·Terry Fry, M.D., Terry Fry, M.D.

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.